fibrinet autologous fibrin & platelet system 2-tube kit
cascade medical enterprises ltd - dispositivi per la preparazione automatica di gel di piastrine (escluse le sacche)
cascade autologous platelet system prp injection kit
cascade medical enterprises ltd - dispositivi per la preparazione automatica di gel di piastrine (escluse le sacche)
the magellanᆴ autologous platelet separator
arteriocyte medical systems - centrifughe
magellanᆴ autologous platelet separator disposable kits
arteriocyte medical systems - strumentazione varia per esplorazioni funzionali ed interventi terapeutici non altrimenti classificata
cascade autologous platelet system prp injection kit
cascade medical enterprises ltd - dispositivi per la preparazione automatica di gel di piastrine (escluse le sacche)
fibrinet autologous fibrin & platelet system 2-tube kit
cascade medical enterprises ltd - dispositivi per la preparazione automatica di gel di piastrine (escluse le sacche)
activat active autologous thrombin (kit per la preparazione di trombina autologa)
cytomedix, inc. - dispositivi per emotrasfusione ed ematologia - altri
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - linfoma, cellule del mantello - agenti antineoplastici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
celution 830/crs single procedure pack
cytori therapeutics inc -
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).